Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2021

Dec 17, 2021

30198_dirs_2021-12-17_c81a2a23-cef7-4f82-8cbb-ed86ae4f2744.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2021-12-15

Reporting Person: Regan Barry J. (EVP Operations)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-12-15 Common Stock A 1671 $0.001 Acquired 13128 Direct

Footnotes

F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock.

F2: Included in this number are 13,128 unvested restricted stock units, 1,671 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024.